查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1666183

全球多平行生物反应器市场 - 2025 至 2033 年

Global Multi Parallel Bioreactors Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球多平行生物反应器市场规模达到 12.8 亿美元，预计到 2033 年将达到 26.1 亿美元，在 2025-2033 年预测期内的复合年增长率为 8.6%。

全球多平行生物反应器市场专注于先进的生物反应器系统，该系统可同时促进多个小规模实验，从而增强生物过程优化。这些系统广泛应用于製药、生物技术、学术研究和生物基产业，可实现高效筛选、製程开发和扩大规模。多平行生物反应器具有即时监控、参数精确控制和高通量功能，在生物製药、疫苗和生物燃料的生产中发挥着至关重要的作用。它们简化和加速流程开发的能力使它们在现代生物製造中不可或缺。

在对生物製剂、生物相似药和个人化医疗的需求不断增长的推动下，市场正在经历快速增长。随着製药和生物技术公司专注于开发针对特定患者的治疗方法，多并行生物反应器对于优化生物过程至关重要。此外，人们对生物塑胶和生物燃料等永续生物基产品的日益重视，也推动了对这些先进生物反应器系统的需求。多并行生物反应器支援可持续且经济高效的生产的能力预计将推动市场进一步扩张。这些因素推动了全球多平行生物反应器市场的扩张。

市场动态：

驱动因素与约束因素

生物製药需求不断成长

受生物製药尤其是个人化医疗需求激增的推动，全球多平行生物反应器市场正在迅速扩张。这些生物反应器有助于优化复杂治疗性蛋白质、单株抗体和疫苗的生产，这些对于满足全球日益增长的医疗保健需求至关重要。多台并联生物反应器可实现高精度控制，这对于维持生物製药产品的品质和一致性至关重要。它们的多功能性受到需要灵活生物製造工艺的行业的高度重视。

多并行生物反应器的主要使用者包括研究机构、合约研究组织（CRO）和合约製造组织（CMO），他们依靠这些系统进行製程开发和大规模生产。自动化、资料分析和一次性生物反应器系统的日益普及等技术进步，透过提高效率、降低污染风险和降低营运成本，进一步推动了市场成长。随着生物製药行业的不断发展，多平行生物反应器在满足该行业对更快、更永续生产日益增长的需求方面发挥着至关重要的作用。

此外，该行业的关键参与者推动了这一市场的成长。例如，2023 年 8 月，Sartorius 和 Repligen Corporation 推出了一款整合式生物反应器系统，该系统将 Sartorius 的 Biostat STR 搅拌釜反应器与 Repligen 的 XCell 交替切向流 (ATF) 上游强化技术结合。此新系统旨在简化生物製药製造商的强化种子培养和 N 灌注实施等流程。所有这些因素都要求全球多平行生物反应器市场。

此外，对生物製剂的需求不断增长，促进了全球多平行生物反应器市场的扩张。

初期投资成本高

全球多平行生物反应器市场受到高初始投资成本的显着影响，这对其广泛采用构成了重大限制，特别是在较小的公司或研究机构中。包括自动化和复杂系统整合在内的先进技术推高了购买和维护这些生物反应器的成本。

这种财务障碍通常会限制它们的使用，只有较大的生物製药公司或资金充足的研究机构才能使用。儘管在可扩展性和精确度方面具有优势，但这些系统所需的前期资本可能会高得令人望而却步。因此，上述因素可能会限制全球多平行生物反应器市场的潜在成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 生物製药需求不断成长
    • 限制
      • 初期投资成本高
    • 机会
    • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大、最畅销品牌的成熟领导者
  • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：按类型

  • 4 生物反应器
  • 8 生物反应器
  • 16 生物反应器
  • 其他的

第 7 章：按产品类型

  • 规模
    • 桌上型生物反应器（最大 15L）
    • 中试规模生物反应器（15-1000L）
    • 工业规模生物反应器（>1000L）
  • 材料
    • 玻璃生物反应器
    • 不銹钢生物反应器
    • 免洗生物反应器

第 8 章：按生物反应器配置

  • 搅拌槽式生物反应器
  • 气升式生物反应器

第 9 章：按情态

  • 手动的
  • 自动的
  • 半自动

第 10 章：按技术

  • 上游
  • 下游

第 11 章：按细胞

  • 哺乳动物细胞
  • 细菌细胞
  • 酵母菌细胞
  • 其他的

第 12 章：按分子

  • 单株抗体
  • 疫苗
  • 重组蛋白
  • 干细胞
  • 基因治疗
  • 其他的

第 13 章：按应用

  • 製药业
  • 生物化工
  • 食品工业
  • 其他的

第 14 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 15 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 16 章：公司简介

  • Sartorius AG
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Infors AG
  • HEL Group
  • Liaoyang Sinotech Technology Development Co., Ltd.
  • TJX Bioengineering
  • HiTec Zang GmbH
  • 2mag AG
  • KBiotech GmBH
  • Belach Bioteknik.
  • Corning Incorporated

第 17 章：附录

简介目录
Product Code: PH9197

The global multi-parallel bioreactors market reached US$ 1.28 billion in 2024 and is expected to reach US$ 2.61 billion by 2033, growing at a CAGR of 8.6 % during the forecast period 2025-2033.

The global multi-parallel bioreactors market focuses on advanced bioreactor systems that facilitate multiple small-scale experiments simultaneously, enhancing bioprocess optimization. These systems are widely used in pharmaceuticals, biotechnology, academic research, and bio-based industries, allowing for efficient screening, process development, and scale-up. With real-time monitoring, precise control over parameters, and high-throughput capabilities, multi-parallel bioreactors play a vital role in the production of biopharmaceuticals, vaccines, and biofuels. Their ability to streamline and accelerate process development makes them indispensable in modern biomanufacturing.

The market is experiencing rapid growth, driven by the increasing demand for biologics, biosimilars, and personalized medicine. As pharmaceutical and biotech companies focus on developing patient-specific treatments, multi-parallel bioreactors have become essential for optimizing bioprocesses. Furthermore, the growing emphasis on sustainable bio-based products, such as bioplastics and biofuels, is fueling the demand for these advanced bioreactor systems. The ability of multi-parallel bioreactors to support sustainable and cost-effective production is expected to drive further market expansion. These factors have driven the global multi-parallel bioreactors market expansion.

Market Dynamics: Drivers & Restraints

Increasing Demand for Biopharmaceuticals

The global market for multi-parallel bioreactors is expanding rapidly, driven by the surging demand for biopharmaceuticals, especially personalized medicine. These bioreactors are instrumental in optimizing the production of complex therapeutic proteins, monoclonal antibodies, and vaccines, all of which are essential to meet the growing healthcare needs worldwide. Multi-parallel bioreactors enable high-precision control, which is crucial for maintaining the quality and consistency of biopharmaceutical products. Their versatility is highly valued across industries that require flexible biomanufacturing processes.

Key users of multi-parallel bioreactors include research institutions, contract research organizations (CROs), and contract manufacturing organizations (CMOs), which rely on these systems for both process development and large-scale production. Technological advancements, such as automation, data analytics, and the growing adoption of single-use bioreactor systems, are further propelling market growth by improving efficiency, reducing contamination risks, and lowering operational costs. As the biopharmaceutical industry continues to evolve, multi-parallel bioreactors play a vital role in meeting the sector's increasing demands for faster and more sustainable production.

Furthermore, key players in the industry launch drive this market growth. For instance, in August 2023, Sartorius and Repligen Corporation launched an integrated bioreactor system that combines Sartorius' Biostat STR stirred-tank reactor with Repligen's XCell Alternating Tangential Flow (ATF) upstream intensification technology. This new system is designed to simplify processes such as intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. All these factors demand the global multi-parallel bioreactors market.

Moreover, the rising demand for biologics contributes to the global multi-parallel bioreactors market expansion.

High Initial Investment Costs

The global multi-parallel bioreactors market is significantly influenced by high initial investment costs, which pose a major restraint for widespread adoption, particularly among smaller companies or research institutions. The advanced technology, including automation and integration of complex systems, drives up the cost of purchasing and maintaining these bioreactors.

This financial barrier often limits their usage to larger biopharmaceutical companies or well-funded research organizations. Despite the advantages in scalability and precision, the upfront capital required for these systems can be prohibitive. Thus, the above factors could be limiting the global multi-parallel bioreactors market's potential growth.

Segment Analysis

The global multi-parallel bioreactors market is segmented based on type, product type, bioreactor configuration, modality, technology, cell, molecule, application, and region.

Type:

The 8 bioreactors segment is expected to dominate the global multi-parallel bioreactors market share

The 8 bioreactors segment holds a major portion of the global multi-parallel bioreactors market share and is expected to continue to hold a significant portion of the global multi-parallel bioreactors market share during the forecast period.

The 8 bioreactor systems are engineered to support high-throughput experimentation by allowing simultaneous testing of multiple conditions. This capability is essential for applications that demand efficiency, such as optimizing bioprocess parameters like temperature, pH, and nutrient concentrations across eight individual bioreactors. The configuration accelerates bioprocess development, enabling researchers to quickly identify optimal conditions for various cell cultures. These systems are particularly valuable in drug development, where time is critical and fast iteration of experiments is necessary.

One of the key advantages of 8 bioreactor systems is their scalability. They can be adapted for both small-scale experiments and larger production runs, making them highly versatile tools for research and development. Additionally, their high throughput significantly boosts research efficiency by enabling multiple experiments to run simultaneously. This feature not only saves time but also reduces costs associated with materials and operations when compared to larger single-use bioreactors. Moreover, the flexibility of these systems allows them to accommodate different cell cultures, including both mammalian and microbial cells, expanding their use across a range of biotechnology fields.

The growing demand for biopharmaceuticals, particularly biologics like monoclonal antibodies and vaccines, is a major driver for the increased use of 8 bioreactor systems. Technological advancements in bioprocessing further enhance the performance and reliability of these systems, making them indispensable in modern biotechnology. The shift towards personalized medicine also calls for adaptable and efficient production systems, which are a defining characteristic of 8 bioreactor configurations. Leading market players such as Sartorius AG and Thermo Fisher Scientific are focusing on improving these systems through innovation and advanced analytics to provide better process control. These factors have solidified the segment's position in the global multi-parallel bioreactors market.

Geographical Analysis

North America is expected to hold a significant position in the global multi-parallel bioreactors market share

North America holds a substantial position in the global multi-parallel bioreactors market and is expected to hold most of the market share, driven by several key factors. One of the primary drivers is the region's strong and well-established biopharmaceutical industry. The U.S. is a global leader in biotechnology and pharmaceutical development, with a high concentration of biopharmaceutical companies, research institutions, and government funding supporting life sciences research.

The increasing demand for biologics, such as monoclonal antibodies and vaccines, is fueling the need for advanced bioprocessing tools like multi-parallel bioreactors. These systems enable high-throughput experimentation and efficient process development, making them indispensable in meeting the growing demand for complex biological therapies.

In addition to the thriving biopharmaceutical sector, technological advancements are also driving the market. The integration of automation, data analytics, and artificial intelligence into bioreactors enhances process efficiency, scalability, and precision, making multi-parallel systems more attractive to companies involved in drug development.

Moreover, the shift toward personalized medicine, which demands flexible and adaptive production systems, further accelerates the adoption of multi-parallel bioreactors. As North American companies continue to invest in innovation and expand their biomanufacturing capabilities, the demand for these systems is expected to continue rising, positioning the region as a dominant player in the global multi-parallel bioreactors market.

Additionally, key players' strategies such as partnerships and collaborations would drive this global multi-parallel bioreactor market growth. For instance, in the U.S., in December 2024, Getinge and 908 Devices partnered to enhance bioreactor monitoring by integrating 908 Devices' MAVEN system with Getinge's bioreactors. This collaboration aims to provide real-time, continuous monitoring of key cell culture parameters, specifically glucose and lactate levels, without the need for manual sampling. Thus, the above factors are consolidating the region's position as a dominant force in the global multi-parallel bioreactors market.

Asia Pacific is growing at the fastest pace in the global multi-parallel bioreactors market share

Asia Pacific holds the fastest pace in the global multi-parallel bioreactors market and is expected to hold most of the market share driven by a combination of factors related to the region's expanding biotechnology and pharmaceutical industries. One of the main drivers is the increasing demand for biopharmaceutical products, especially in countries like China and India, where the biopharmaceutical sector is undergoing significant growth. These nations are investing heavily in biotechnology infrastructure, research and development, and the production of biologics, which has led to a rising need for advanced bioreactor systems like multi-parallel bioreactors.

These systems are essential for accelerating bioprocess development, and optimizing conditions for the production of complex drugs such as monoclonal antibodies and vaccines. Technological advancements in bioprocessing have made multi-parallel bioreactors more attractive to companies in the region. The adoption of automation, data analytics, and single-use technologies has enhanced the efficiency, scalability, and flexibility of bioreactor systems. These innovations are particularly important in addressing the challenges of producing biologics at scale and in a cost-effective manner. With Asia-Pacific's growing emphasis on personalized medicine and the increasing focus on rapid drug development, multi-parallel bioreactors are becoming key tools to meet these evolving demands.

Additionally, key players in the industry launch that would drive these global multi-parallel bioreactors market growth. For instance, in September 2024, VFL Sciences Private Limited introduced the GreatFlo series of benchtop fermenters/bioreactors, including the GreatFlo Expert and GreatFlo Proficient models. These systems are designed for versatility and come in capacities of up to 10 liters, with both autoclavable and in-situ sterilizable versions. They serve as advanced alternatives to existing models, offering cutting-edge features for fermentation and bioprocessing applications. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global multi-parallel bioreactors market.

Competitive Landscape

The major global players in the multi-parallel bioreactors market include Sartorius AG, Infors AG, H.E.L Group, Liaoyang Sinotech Technology Development Co., Ltd., TJX Bioengineering, HiTec Zang GmbH, 2mag AG, KBiotech GmBH, Belach Bioteknik., and Corning Incorporated among others.

Key Developments

  • In December 2024, METHER launched a new product in Shanghai called the Respiratory Bioreactor. While specific details about the bioreactor's capabilities were not provided in the available sources, it is likely a specialized device designed for biomedical and laboratory applications.
  • In March 2024, CytoNiche launched the 3D FloTrix vivaROCK Bioreactor System, a single-use rocking bioreactor designed for high-quality, large-scale 3D cell culture. This system is particularly suited for applications in scientific research, process development, and manufacturing.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-parallel bioreactors market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Product Type
  • 3.3. Snippet by Bioreactor Configuration
  • 3.4. Snippet by Modality
  • 3.5. Snippet by Technology
  • 3.6. Snippet by Cell
  • 3.7. Snippet by Molecule
  • 3.8. Snippet by Application
  • 3.9. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Biopharmaceuticals
    • 4.1.2. Restraints
      • 4.1.2.1. High Initial Investment Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
  • 5.2. Emerging Pioneers and Prominent Players
  • 5.3. Established leaders with largest largest-selling Brand
  • 5.4. Market leaders with established Product
  • 5.5. CXO Perspectives
  • 5.6. Latest Developments and Breakthroughs
  • 5.7. Case Studies/Ongoing Research
  • 5.8. Regulatory and Reimbursement Landscape
  • 5.9. North America
  • 5.10. Europe
  • 5.11. Asia Pacific
  • 5.12. Latin America
  • 5.13. Middle East & Africa
  • 5.14. Porter's Five Force Analysis
  • 5.15. Supply Chain Analysis
  • 5.16. Patent Analysis
  • 5.17. SWOT Analysis
  • 5.18. Unmet Needs and Gaps
  • 5.19. Recommended Strategies for Market Entry and Expansion
  • 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.21. Pricing Analysis and Price Dynamics
  • 5.22. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. 4 Bioreactors*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. 8 Bioreactors
  • 6.4. 16 Bioreactors
  • 6.5. Others

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Scale*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Benchtop Bioreactors (Up to 15L)
    • 7.2.4. Pilot Scale Bioreactors (15-1000L)
    • 7.2.5. Industrial Scale Bioreactors (>1000L)
  • 7.3. Material
    • 7.3.1. Glass Bioreactors
    • 7.3.2. Stainless Steel Bioreactors
    • 7.3.3. Single-Use Bioreactors

8. By Bioreactor Configuration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 8.1.2. Market Attractiveness Index, By Bioreactor Configuration
  • 8.2. Stirred-Tank Bioreactors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Airlift Bioreactors

9. By Modality

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 9.1.2. Market Attractiveness Index, By Modality
  • 9.2. Manual*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Automatic
  • 9.4. Semi-Automatic

10. By Technology

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2. Market Attractiveness Index, By Technology
  • 10.3. Upstream*
    • 10.3.1. Introduction
    • 10.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.4. Downstream

11. By Cell

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 11.1.2. Market Attractiveness Index, By Cell
  • 11.2. Mammalian Cells*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Bacterial Cells
  • 11.4. Yeast Cells
  • 11.5. Others

12. By Molecule

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 12.1.2. Market Attractiveness Index, By Molecule
  • 12.2. Monoclonal Antibodies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Vaccines
  • 12.4. Recombinant Proteins
  • 12.5. Stem Cells
  • 12.6. Gene Therapy
  • 12.7. Others

13. By Application

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.1.2. Market Attractiveness Index, By Application
  • 13.2. Pharmaceutical Industry*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Biochemical Engineering
  • 13.4. Food Industry
  • 13.5. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.11.1. U.S.
      • 14.2.11.2. Canada
      • 14.2.11.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.11.1. Germany
      • 14.3.11.2. U.K.
      • 14.3.11.3. France
      • 14.3.11.4. Spain
      • 14.3.11.5. Italy
      • 14.3.11.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.11.1. Brazil
      • 14.4.11.2. Argentina
      • 14.4.11.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.11.1. China
      • 14.5.11.2. India
      • 14.5.11.3. Japan
      • 14.5.11.4. South Korea
      • 14.5.11.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Positioning/Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Sartorius AG*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio
      • 16.1.2.1. Product Description
      • 16.1.2.2. Product Key Performance Indicators (KPIs)
      • 16.1.2.3. Historic and Forecasted Product Sales
      • 16.1.2.4. Product Sales Volume
    • 16.1.3. Financial Overview
      • 16.1.3.1. Company Revenue's
      • 16.1.3.2. Geographical Revenue Shares
      • 16.1.3.3. Revenue Forecasts
    • 16.1.4. Key Developments
      • 16.1.4.1. Mergers & Acquisitions
      • 16.1.4.2. Key Product Development Activities
      • 16.1.4.3. Regulatory Approvals etc.
    • 16.1.5. SWOT Analysis
  • 16.2. Infors AG
  • 16.3. H.E.L Group
  • 16.4. Liaoyang Sinotech Technology Development Co., Ltd.
  • 16.5. TJX Bioengineering
  • 16.6. HiTec Zang GmbH
  • 16.7. 2mag AG
  • 16.8. KBiotech GmBH
  • 16.9. Belach Bioteknik.
  • 16.10. Corning Incorporated

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us